Glycominds is employing its proprietary approach and knowledge in multiple sclerosis biomarkers to develop personalized medicine tools for use by physicians.

The gMS^®DMT approach will help physicians optimize treatment regimens for patients resulting in either better outcomes and/or reduced costs by identifying which patients will likely response best to a specific therapeutic treatment. Glycominds’ technology links biomarkers underlying immune system of any individual patient to the best therapeutic choice. Initial results show that our biomarkers can identify patients who will respond to specific therapies.

 

 

We are continuing our research in this area and invite Healthcare providers and Pharmaceutical companies to join our efforts.